AAAAAA

   
Results: 1-8 |
Results: 8
Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer
Authors: Boyer, MJ Mitchell, P Goldstein, D Millward, MJ Olver, IN Clarke, SJ Richardson, G Davis, I
Citation: Mj. Boyer et al., Phase II study of paclitaxel and oral etoposide in patients with locally advanced or metastatic non-small cell lung cancer, LUNG CANC, 32(1), 2001, pp. 89-94
Optimizing the erythromycin breath test for use in cancer patients
Authors: Rivory, LP Slaviero, K Seale, JP Hoskins, JM Boyer, M Beale, PJ Millward, MJ Bishop, JF Clarke, SJ
Citation: Lp. Rivory et al., Optimizing the erythromycin breath test for use in cancer patients, CLIN CANC R, 6(9), 2000, pp. 3480-3485
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel withperipheral blood progenitor cell and filgrastim support for metastatic andlocally advanced breast cancer: Results of a phase I study
Authors: Prince, HM Millward, MJ Rischin, D Blakey, D Francis, P Gates, P Chapple, P Quinn, M Juneja, S Wolf, M Januszewicz, EH Seymour, JF Brettell, M Strickland, A Zalcberg, J Richardson, G Scarlett, J Briggs, P Toner, GC
Citation: Hm. Prince et al., Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel withperipheral blood progenitor cell and filgrastim support for metastatic andlocally advanced breast cancer: Results of a phase I study, ANN ONCOL, 10(4), 1999, pp. 479-481
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer
Authors: Prince, HM Gardyn, J Millward, MJ Rischin, D Francis, P Gates, P Chapple, P Quinn, M Juneja, S Wolf, M Januszewicz, EH Richardson, G Scarlett, J Briggs, P Brettell, M Toner, GC
Citation: Hm. Prince et al., Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer, BONE MAR TR, 23(5), 1999, pp. 427-435
A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer
Authors: Rischin, D Webster, LK Millward, MJ Toner, GC Nawaratne, S Ganju, V Francis, P Bishop, JF
Citation: D. Rischin et al., A phase I and pharmacokinetic study of paclitaxel and epirubicin in advanced cancer, INV NEW DR, 17(1), 1999, pp. 73-80
Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer
Authors: Le Chevalier, T Berille, J Zalcberg, JR Millward, MJ Monnier, A Douillard, JY McKeage, MJ James, R Soulas, F Loret, C Bougon, N Bizzari, JP
Citation: T. Le Chevalier et al., Overview of docetaxel (Taxotere)/cisplatin combination in non-small cell lung cancer, SEMIN ONCOL, 26(3), 1999, pp. 13-18
A phase II study of Gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
Authors: Friedlander, M Millward, MJ Bell, D Bugat, R Harnett, P Moreno, JA Campbell, L Varette, C Ripoche, V Kayitalire, L
Citation: M. Friedlander et al., A phase II study of Gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer, ANN ONCOL, 9(12), 1998, pp. 1343-1345
Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: A randomized, crossover comparison
Authors: Toner, GC Shapiro, JD Laidlaw, CR Rischin, D Millward, MJ Wolf, M Januszewicz, H Mitchell, SV Curran, AC Matthews, JP Bishop, JF
Citation: Gc. Toner et al., Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: A randomized, crossover comparison, J CL ONCOL, 16(12), 1998, pp. 3874-3879
Risultati: 1-8 |